It is with deep sadness that we announce our dear friend and colleague Donald Macpherson passed away recently after a long illness. Donald was an enthusiastic supporter of Rosetta and we are very grateful for his advice and guidance over many years. He will be very much missed. Our thoughts and condolences go out to Donald’s family and friends during this difficult time.
Biotech
Immunocore focuses on the development of immunotherapeutic drugs for the treatment of cancer, and infectious diseases. The company develops drugs using proprietary T cell receptor (TCR) technology. Immunocore launched KIMMTRAK® (tebentafusp-tebn) in 2021 for metastatic uveal melanoma. Immunocore listed on NASDAQ in 2021.
CEO
Bahija Jallal
Oncology and infectious disease
Oxfordshire, UK
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
